source
- Evommune's MRGPRX2 antagonist fails second Phase 2b trial in atopic dermatitisEvommune reported that its experimental small-molecule antagonist of the MRGPRX2 receptor did not meet its primary endpoints in a Phase 2b study in patients with atopic dermatitis. The study, cond…
- Roivant reports record-breaking Phase 2 results for PH-ILD drug mosliciguat, starts Phase 3Roivant announced that its experimental drug mosliciguat met all primary and secondary endpoints in a Phase 2 study in patients with pulmonary hypertension associated with interstitial lung disease…